The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Gastroesophageal Reflux Disease Therapeutics Global Market Report 2023, the gastroesophageal reflux disease therapeutics market is expected to show significant growth in the forecast period.

Key insights from the gastroesophageal reflux disease therapeutics market forecast include:

1. Market Size

The global gastroesophageal reflux disease therapeutics market is expected to grow from $5.56 billion in 2022 to $5.78 billion in 2023 at a compound annual growth rate (CAGR) of 3.9The size of gastroesophageal reflux disease therapeutics market is expected to reach $6.82 billion in 2027 at a CAGR of 4.2%.

2. Major Driver

The prevalence of gastroesophageal reflux disease is expected to propel the growth of the gastroesophageal reflux disease therapeutics market moving forward. For instance, in September 2022, according to the article published by WebMed, a US-based online publisher of news and information about human health, more than 60 million American adults suffer heartburn at least once a month, and more than 15 million suffer daily. Furthermore, in July 2022, statistics shared by the National Library of Medicine, a US-based federal medical library, GERD is one of the most often diagnosed digestive illnesses in the United States, with a 20% prevalence, resulting in a significant economic burden in direct and indirect expenditures as well as a negative impact on quality of life. Therefore, the prevalence of gastroesophageal reflux disease is expected to drive the growth of the gastroesophageal reflux disease therapeutics market.

View More On The Gastroesophageal Reflux Disease Therapeutics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

3. Key Trend

Product innovations are the key trend gaining popularity in the gastroesophageal reflux disease therapeutics market. Major companies operating in the gastroesophageal reflux disease therapeutics market are focusing on innovative medications to sustain their position in the market. For instance, in March 2021, Xiromed LLC, a US-based integrated generic company, launched Omeprazole Delayed-Release Capsules (generic to Prilosec) to treat frequent heartburn in gastroesophageal reflux. Omeprazole is a proton pump inhibitor (PPI) medication designed to treat some stomach and esophageal issues (such as acid reflux and ulcers) by lowering the quantity of acid produced by the stomach that alleviating symptoms such as heartburn, trouble swallowing, and persistent cough. This drug helps cure acid damage to the stomach and esophagus, prevents ulcers, and may help prevent esophageal cancer.

4. Largest Region

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2022.

5. Major Players

Major players in the gastroesophageal reflux disease therapeutics market are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd., Bruker Corp, Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, and Addex Pharmacetuicals.

Request A Sample Of The Global Gastroesophageal Reflux Disease Therapeutics Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12058&type=smp

Key Gastroesophageal Reflux Disease Therapeutics Market Segments
The global gastroesophageal reflux disease therapeutics market is segmented –
1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
4) By Application: Crohn’s Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

The Gastroesophageal Reflux Disease Therapeutics Global Market Report 2023  provides an in-depth analysis on the gastroesophageal reflux disease therapeutics market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the gastroesophageal reflux disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Reflux Testing Products Global Market Report 2023
Gastrointestinal Devices Global Market Report 2023
Gastrointestinal Bleeding Treatment Devices Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model